Immune Response After Cochlear Implantation.
cochleostomy
dexamethasone
drug delivery
fibrosis
neuronal degeneration
steroids
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
10
2019
accepted:
07
04
2020
entrez:
2
6
2020
pubmed:
2
6
2020
medline:
2
6
2020
Statut:
epublish
Résumé
A cochlear implant (CI) is an electronic device that enables hearing recovery in patients with severe to profound hearing loss. Although CIs are a successful treatment for profound hearing impairment, their effectivity may be improved by reducing damages associated with insertion of electrodes in the cochlea, thus preserving residual hearing ability. Inner ear trauma leads to inflammatory reactions altering cochlear homeostasis and reducing post-operative audiological performances and electroacoustic stimulation. Strategies to preserve residual hearing ability led to the development of medicated devices to minimize CI-induced cochlear injury. Dexamethasone-eluting electrodes recently showed positive outcomes. In previous studies by our research group, intratympanic release of dexamethasone for 14 days was able to preserve residual hearing from CI insertion trauma in a Guinea pig model. Long-term effects of dexamethasone-eluting electrodes were therefore evaluated in the same animal model. Seven Guinea pigs were bilaterally implanted with medicated rods and four were implanted with non-eluting ones. Hearing threshold audiograms were acquired prior to implantation and up to 60 days by recording compound action potentials. For each sample, we examined the amount of bone and fibrous connective tissue grown within the scala tympani in the basal turn of the cochlea, the cochleostomy healing, the neuronal density, and the correlation between electrophysiological parameters and histological results. Detection of tumor necrosis factor alpha, interleukin-6, and foreign body giant cells showed that long-term electrode implantation was not associated with an ongoing inflammation. Growth of bone and fibrous connective tissue around rods induced by CI was reduced in the scala tympani by dexamethasone release. For cochleostomy sealing, dexamethasone-treated animals showed less bone tissue growth than negative. Dexamethasone did not affect cell density in the spiral ganglion. Overall, these results support the use of dexamethasone as anti-inflammatory additive for eluting electrodes able to protect the cochlea from CI insertion trauma.
Identifiants
pubmed: 32477241
doi: 10.3389/fneur.2020.00341
pmc: PMC7240074
doi:
Types de publication
Journal Article
Langues
eng
Pagination
341Informations de copyright
Copyright © 2020 Simoni, Gentilin, Candito, Borile, Romanato, Chicca, Nordio, Aspidistria, Martini, Cazzador and Astolfi.
Références
Semin Hear. 2018 Nov;39(4):414-427
pubmed: 30374212
Otol Neurotol. 2014 Sep;35(8):1440-5
pubmed: 24853240
Colloids Surf B Biointerfaces. 2019 Jan 1;173:400-406
pubmed: 30321797
PLoS One. 2018 Mar 30;13(3):e0195230
pubmed: 29601595
Otol Neurotol. 2018 Mar;39(3):284-293
pubmed: 29342037
Int J Mol Med. 2018 Apr;41(4):2028-2036
pubmed: 29393368
Int J Pediatr Otorhinolaryngol. 2015 May;79(5):725-31
pubmed: 25799382
PLoS One. 2012;7(12):e51499
pubmed: 23240031
Hear Res. 2016 Jul;337:12-24
pubmed: 26892906
Hear Res. 2016 Jun;336:44-52
pubmed: 27109196
Biomaterials. 2011 Jul;32(21):4714-24
pubmed: 21477859
Otol Neurotol. 2001 Jan;22(1):18-23
pubmed: 11314710
Hear Res. 2004 Oct;196(1-2):58-68
pubmed: 15464302
Hear Res. 2017 May;348:44-53
pubmed: 28216124
Hear Res. 2016 Nov;341:43-49
pubmed: 27519654
Clin Otolaryngol Allied Sci. 2000 Dec;25(6):492-4
pubmed: 11122286
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Otol Neurotol. 2017 Jan;38(1):19-30
pubmed: 27779563
Laryngoscope. 2007 Jan;117(1):58-62
pubmed: 17202931
J Biomed Mater Res B Appl Biomater. 2014 Feb;102(2):267-73
pubmed: 23997036
Int J Pediatr Otorhinolaryngol. 2013 Jun;77(6):885-93
pubmed: 23578804
Adv Healthc Mater. 2019 Feb;8(4):e1801451
pubmed: 30658015
Hear Res. 2002 May;167(1-2):61-70
pubmed: 12117531
J Pharmacol Sci. 2005 Oct;99(2):191-4
pubmed: 16210774
Otolaryngol Head Neck Surg. 2007 Nov;137(5):747-52
pubmed: 17967639
J Acoust Soc Am. 2008 Oct;124(4):2164-73
pubmed: 19062856
Hear Res. 2005 Apr;202(1-2):13-20
pubmed: 15811694
J Biomed Opt. 2018 Mar;23(9):1-9
pubmed: 29516689
Dermatol Surg. 2018 Sep;44(9):1174-1182
pubmed: 29757858
PLoS One. 2017 Aug 31;12(8):e0183820
pubmed: 28859106
Acta Otorhinolaryngol Ital. 2016 Dec;36(6):513-519
pubmed: 28177335
Otol Neurotol. 2017 Aug;38(7):970-977
pubmed: 28538471
Hear Res. 2013 Dec;306:145-55
pubmed: 23968822
Hear Res. 2014 Dec;318:11-7
pubmed: 25285622
J Biomed Mater Res A. 2017 Apr;105(4):1105-1111
pubmed: 28093892
Cytotherapy. 2017 Aug;19(8):909-915
pubmed: 28532627
PLoS One. 2016 Feb 03;11(2):e0147552
pubmed: 26840740
Hear Res. 2017 Dec;356:93-103
pubmed: 29102129
Laryngoscope. 2006 Apr;116(4):627-9
pubmed: 16585870
World J Otorhinolaryngol Head Neck Surg. 2018 Mar 06;3(4):211-213
pubmed: 29780964
Cochrane Database Syst Rev. 2011 Jul 06;(7):CD008514
pubmed: 21735432